These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 26909746)

  • 1. Acquired skin hyperpigmentation following intravenous polymyxin B treatment: a cohort study.
    Mattos KP; Lloret GR; Cintra ML; Gouvêa IR; Betoni TR; Mazzola PG; Moriel P
    Pigment Cell Melanoma Res; 2016 May; 29(3):388-90. PubMed ID: 26909746
    [No Abstract]   [Full Text] [Related]  

  • 2. Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process.
    Mattos KPH; Cintra ML; Gouvêa IR; Ferreira LÁ; Velho PENF; Moriel P
    J Clin Pharm Ther; 2017 Oct; 42(5):573-578. PubMed ID: 28497462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathological findings of pigmented lesion and recovery of natural skin colour in a patient with polymyxin B-associated diffuse hyperpigmentation.
    Zavascki AP; Schuster LF; Duquia RP
    Int J Antimicrob Agents; 2016 Nov; 48(5):579-580. PubMed ID: 27720305
    [No Abstract]   [Full Text] [Related]  

  • 4. Polymyxin B Induced Generalized Hyperpigmentation in Neonates.
    Gothwal S; Meena K; Sharma SD
    Indian J Pediatr; 2016 Feb; 83(2):179-80. PubMed ID: 26088547
    [No Abstract]   [Full Text] [Related]  

  • 5. Polymyxin B-induced skin hyperpigmentation: a rare case report and literature review.
    Zheng G; Cao L; Che Z; Mao E; Chen E; He J
    BMC Pharmacol Toxicol; 2018 Jul; 19(1):41. PubMed ID: 29973293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Head and Neck Hyperpigmentation Probably Associated with Polymyxin B Therapy.
    Zavascki AP; Manfro RC; Maciel RA; Falci DR
    Ann Pharmacother; 2015 Oct; 49(10):1171-2. PubMed ID: 26187742
    [No Abstract]   [Full Text] [Related]  

  • 7. Polymyxin B-induced skin hyperpigmentation.
    Li YM; Milikowski C; Selvaggi G; Abbo LM; Skiada D; Galimberti F
    Transpl Infect Dis; 2020 Oct; 22(5):e13312. PubMed ID: 32386075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymyxin B versus other antimicrobials for the treatment of pseudomonas aeruginosa bacteraemia.
    Kvitko CH; Rigatto MH; Moro AL; Zavascki AP
    J Antimicrob Chemother; 2011 Jan; 66(1):175-9. PubMed ID: 20961911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Face skin hyperpigmentation during pegylated interferon and ribavirin therapy.
    Yaşar B; Yaşar Ş; Güneş P
    Turk J Gastroenterol; 2015 Mar; 26(2):189-90. PubMed ID: 25835121
    [No Abstract]   [Full Text] [Related]  

  • 10. Higher incidence of neurotoxicity and skin hyperpigmentation in renal transplant patients treated with polymyxin B.
    Zhou Y; Li Y; Xie X; Song L; Lan G; Sun B; Tang T; Yan H; Zhang B; Xu P
    Br J Clin Pharmacol; 2022 Nov; 88(11):4742-4750. PubMed ID: 35508710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic.
    Elias LS; Konzen D; Krebs JM; Zavascki AP
    J Antimicrob Chemother; 2010 Oct; 65(10):2231-7. PubMed ID: 20685752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy.
    Kubin CJ; Ellman TM; Phadke V; Haynes LJ; Calfee DP; Yin MT
    J Infect; 2012 Jul; 65(1):80-7. PubMed ID: 22326553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.
    Akajagbor DS; Wilson SL; Shere-Wolfe KD; Dakum P; Charurat ME; Gilliam BL
    Clin Infect Dis; 2013 Nov; 57(9):1300-3. PubMed ID: 23840000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections.
    Sobieszczyk ME; Furuya EY; Hay CM; Pancholi P; Della-Latta P; Hammer SM; Kubin CJ
    J Antimicrob Chemother; 2004 Aug; 54(2):566-9. PubMed ID: 15269195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of intravenous polymyxin B in critically ill patients.
    Zavascki AP; Goldani LZ; Cao G; Superti SV; Lutz L; Barth AL; Ramos F; Boniatti MM; Nation RL; Li J
    Clin Infect Dis; 2008 Nov; 47(10):1298-304. PubMed ID: 18840079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit.
    Holloway KP; Rouphael NG; Wells JB; King MD; Blumberg HM
    Ann Pharmacother; 2006 Nov; 40(11):1939-45. PubMed ID: 17018688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffuse cutaneous hyperpigmentation due to tigecycline or polymyxin B.
    Knueppel RC; Rahimian J
    Clin Infect Dis; 2007 Jul; 45(1):136-8. PubMed ID: 17554719
    [No Abstract]   [Full Text] [Related]  

  • 18. Anaphylaxis to polymyxin B-trimethoprim eye drops.
    Henao MP; Ghaffari G
    Ann Allergy Asthma Immunol; 2016 Apr; 116(4):372. PubMed ID: 26922212
    [No Abstract]   [Full Text] [Related]  

  • 19. Postoperative polymyxin B hemoperfusion and mortality in patients with abdominal septic shock: a propensity-matched analysis.
    Iwagami M; Yasunaga H; Doi K; Horiguchi H; Fushimi K; Matsubara T; Yahagi N; Noiri E
    Crit Care Med; 2014 May; 42(5):1187-93. PubMed ID: 24365858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinically presumptive toxicity of various ear-drops].
    Goffinet M
    Acta Otorhinolaryngol Belg; 1977; 31(6):585-90. PubMed ID: 202140
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.